Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
07 Apr 2022
07 Apr 2022
Historique:
received:
06
10
2021
accepted:
24
02
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.
Identifiants
pubmed: 35393553
doi: 10.1038/s41698-022-00267-7
pii: 10.1038/s41698-022-00267-7
pmc: PMC8990074
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205426
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232097
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Cancer. 2020 Mar 1;126(5):994-1003
pubmed: 31809562
J Clin Invest. 2003 Feb;111(4):515-27
pubmed: 12588890
Int Arch Med. 2012 Jan 26;5(1):2
pubmed: 22281066
Ann Transl Med. 2020 Oct;8(20):1310
pubmed: 33209890
Gastroenterol Rep (Oxf). 2016 Nov;4(4):272-280
pubmed: 27174435
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Semin Dial. 2004 Nov-Dec;17(6):432-7
pubmed: 15660573
J Immunother Cancer. 2018 Nov 23;6(1):129
pubmed: 30470260
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Nutr J. 2010 Dec 22;9:69
pubmed: 21176210
Nat Commun. 2021 Feb 1;12(1):729
pubmed: 33526794
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Biotechnol. 2022 Apr;40(4):499-506
pubmed: 34725502
Ann Oncol. 2020 Sep;31(9):1115-1118
pubmed: 32771306
Nat Med. 2020 May;26(5):693-698
pubmed: 32405063
Nat Med. 2019 Nov;25(11):1715-1720
pubmed: 31700181
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581042
Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30
pubmed: 23602134
Nat Genet. 2021 Jan;53(1):11-15
pubmed: 33398197
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
J Immunother Cancer. 2019 Jul 19;7(1):192
pubmed: 31324223